Inhibrx Biosciences (INBX) Total Current Liabilities (2023 - 2025)

Inhibrx Biosciences (INBX) has 3 years of Total Current Liabilities data on file, last reported at $33.8 million in Q4 2025.

• Total Current Liabilities for Q4 2025 came in at $33.8 million, down 17.02% year-over-year; the trailing twelve-month figure through Dec 2025 was $33.8 million (down 17.02% YoY), and the FY2025 annual result was $33.8 million, down 17.02% from the prior year.
• Total Current Liabilities fell to $33.8 million in Q4 2025 per INBX's latest filing, from $36.0 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $56.3 million in Q4 2023 and troughed at $33.8 million in Q4 2025.
• A 3-year average of $41.6 million and a median of $39.9 million in 2024 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2024 and 2025: Total Current Liabilities slipped 27.67% in 2024, then retreated 0.29% in 2025.
• A 3-year view of Total Current Liabilities shows it stood at $56.3 million in 2023, then fell by 27.67% to $40.7 million in 2024, then dropped by 17.02% to $33.8 million in 2025.
• Business Quant data shows INBX's Total Current Liabilities at $33.8 million in Q4 2025, $36.0 million in Q3 2025, and $38.9 million in Q2 2025.